153 related articles for article (PubMed ID: 15347714)
1. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
Dimitrakopoulou-Strauss A; Strauss LG; Burger C; Rühl A; Irngartinger G; Stremmel W; Rudi J
J Nucl Med; 2004 Sep; 45(9):1480-7. PubMed ID: 15347714
[TBL] [Abstract][Full Text] [Related]
2. PET-FDG as predictor of therapy response in patients with colorectal carcinoma.
Dimitrakopoulou-Strauss A; Strauss LG; Rudi J
Q J Nucl Med; 2003 Mar; 47(1):8-13. PubMed ID: 12714949
[TBL] [Abstract][Full Text] [Related]
3. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET.
Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Haberkorn U; Strauss LG
Clin Nucl Med; 2009 Sep; 34(9):576-84. PubMed ID: 19692817
[TBL] [Abstract][Full Text] [Related]
4. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis.
Okazumi S; Dimitrakopoulou-Strauss A; Schwarzbach MH; Strauss LG
Hell J Nucl Med; 2009; 12(3):223-8. PubMed ID: 19936332
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET in evaluating patients treated for metastatic colorectal cancer: can we predict prognosis?
Metser U
J Nucl Med; 2004 Sep; 45(9):1428-30. PubMed ID: 15347706
[No Abstract] [Full Text] [Related]
6. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
[TBL] [Abstract][Full Text] [Related]
7. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study.
Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Eisenhut M; Pan L; Haberkorn U; Strauss LG
Mol Imaging Biol; 2007; 9(5):308-17. PubMed ID: 17623254
[TBL] [Abstract][Full Text] [Related]
8. Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection?
Strauss LG; Klippel S; Pan L; Schönleben K; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):868-77. PubMed ID: 17219134
[TBL] [Abstract][Full Text] [Related]
9. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
[TBL] [Abstract][Full Text] [Related]
10. Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.
Strauss LG; Hoffend J; Koczan D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1226-34. PubMed ID: 19280186
[TBL] [Abstract][Full Text] [Related]
11. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions.
Dimitrakopoulou-Strauss A; Strauss LG; Heichel T; Wu H; Burger C; Bernd L; Ewerbeck V
J Nucl Med; 2002 Apr; 43(4):510-8. PubMed ID: 11937595
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.
Itti E; Lin C; Dupuis J; Paone G; Capacchione D; Rahmouni A; Haioun C; Meignan M
J Nucl Med; 2009 Apr; 50(4):527-33. PubMed ID: 19289424
[TBL] [Abstract][Full Text] [Related]
13. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
Dose Schwarz J; Bader M; Jenicke L; Hemminger G; Jänicke F; Avril N
J Nucl Med; 2005 Jul; 46(7):1144-50. PubMed ID: 16000283
[TBL] [Abstract][Full Text] [Related]
14. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
15. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
[TBL] [Abstract][Full Text] [Related]
16. Shortened PET data acquisition protocol for the quantification of 18F-FDG kinetics.
Strauss LG; Dimitrakopoulou-Strauss A; Haberkorn U
J Nucl Med; 2003 Dec; 44(12):1933-9. PubMed ID: 14660719
[TBL] [Abstract][Full Text] [Related]
17. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.
Dimitrakopoulou-Strauss A; Strauss LG; Egerer G; Vasamiliette J; Schmitt T; Haberkorn U; Kasper B
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1481-9. PubMed ID: 20336454
[TBL] [Abstract][Full Text] [Related]
18. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.
Lin C; Itti E; Haioun C; Petegnief Y; Luciani A; Dupuis J; Paone G; Talbot JN; Rahmouni A; Meignan M
J Nucl Med; 2007 Oct; 48(10):1626-32. PubMed ID: 17873129
[TBL] [Abstract][Full Text] [Related]
19. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]